ESC Premium Access

Drug therapy in heart failure

Event: ESC CONGRESS 2016
Topic: Pharmacologic therapy
Session type: Advances in Science
Date: 29 August 2016
Time: 14:00 - 15:30

Session

5 presentations in this session

State of the art in drug therapy in chronic heart failure.

Speaker: Professor D. van Veldhuisen (Groningen, NL)
Thumbnail

Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

Speaker: Doctor G. Savarese (Stockholm, SE)
Thumbnail

Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)

Speaker: Professor W. Kosmala (Wroclaw, PL)
Thumbnail

Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors

Speaker: Doctor P. Paren (Mölndal, SE)
Thumbnail

Future direction for research in drug therapy.

Speaker: Professor J. Teerlink (San Francisco, US)
Thumbnail

5 speakers from this session

Professor Dirk van Veldhuisen

University Medical Center Groningen, Groningen (Netherlands (The))
12 presentations
0 follower

Doctor Gianluigi Savarese

Karolinska Institute, Stockholm (Sweden)
16 presentations
0 follower

Professor Wojciech Kosmala

Wroclaw Medical University, Wroclaw (Poland)
3 presentations
0 follower

Doctor Par Paren

Sahlgrenska University Hospital/Mölndal, Department of Internal Medicine, Mölndal (Sweden)
0 follower

Professor John R Teerlink

San Francisco Veterans Affairs Medical Center, San Francisco (United States of America)
18 presentations
0 follower

This platform is supported by

logo Novo Nordisk